247 related articles for article (PubMed ID: 23199508)
41. New therapies on the horizon for hepatitis C: are we close?
De Francesco R; Rice CM
Clin Liver Dis; 2003 Feb; 7(1):211-42, xi. PubMed ID: 12691468
[TBL] [Abstract][Full Text] [Related]
42. [Evaluation and application of natural products for viral infections].
Hayashi K; Hayashi T; Lee JB
Yakugaku Zasshi; 2010 Feb; 130(2):171-6. PubMed ID: 20118639
[TBL] [Abstract][Full Text] [Related]
43. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
44. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
45. MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication.
Chou WW; Huang CF; Yeh ML; Tsai YS; Hsieh MY; Huang CI; Huang JF; Tsai PC; Hsi E; Juo SH; Tsai WL; Chuang WL; Yu ML; Dai CY
J Mol Med (Berl); 2016 Mar; 94(3):311-20. PubMed ID: 26489607
[TBL] [Abstract][Full Text] [Related]
46. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
Cristina J; del Pilar Moreno M; Moratorio G
Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
[TBL] [Abstract][Full Text] [Related]
47. [Antiviral agents for analyzing virus life cycle: chemical genetics for virology].
Watashi K
Yakugaku Zasshi; 2013; 133(11):1169-75. PubMed ID: 24189558
[TBL] [Abstract][Full Text] [Related]
48. Convert hepatitis C virus into a non-enveloped virus like hepatitis A, by targeting its envelope rather than the RNA.
Helmy A
Med Hypotheses; 2006; 66(4):847-50. PubMed ID: 16229965
[TBL] [Abstract][Full Text] [Related]
49. Resistance mutations against HCV protease inhibitors and antiviral drug design.
Shang L; Lin K; Yin Z
Curr Pharm Des; 2014; 20(5):694-703. PubMed ID: 23688081
[TBL] [Abstract][Full Text] [Related]
50. Roles of phosphoinositides and phosphoinositides kinases in hepatitis C virus RNA replication.
Lee C
Arch Pharm Res; 2012 Oct; 35(10):1701-11. PubMed ID: 23139120
[TBL] [Abstract][Full Text] [Related]
51. [Antiviral activity in vitro and pharmacokinetics of HCV entry inhibitor AVR560].
Ivashchenko AV; Iamanushkin PM; Mit'kin OD; Ezhova EV; Korzinov OM; Bulanova EA; Koriakova AG; Vyshemirskaia PV; Bychko VV; Ivashchenko AA
Eksp Klin Farmakol; 2014; 77(10):38-43. PubMed ID: 25518527
[TBL] [Abstract][Full Text] [Related]
52. Modulation of host metabolism as a target of new antivirals.
Ikeda M; Kato N
Adv Drug Deliv Rev; 2007 Oct; 59(12):1277-89. PubMed ID: 17897752
[TBL] [Abstract][Full Text] [Related]
53. Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.
Hu Z; Hu X; He S; Yim HJ; Xiao J; Swaroop M; Tanega C; Zhang YQ; Yi G; Kao CC; Marugan J; Ferrer M; Zheng W; Southall N; Liang TJ
Antiviral Res; 2015 Dec; 124():20-9. PubMed ID: 26515788
[TBL] [Abstract][Full Text] [Related]
54. Locking out hepatitis C.
Gerold G; Rice CM
Nat Med; 2011 May; 17(5):542-4. PubMed ID: 21546968
[No Abstract] [Full Text] [Related]
55. Gumming up the works: DNA polymers as HCV entry inhibitors.
Counihan NA; Lindenbach BD
Gastroenterology; 2009 Aug; 137(2):427-30. PubMed ID: 19563837
[No Abstract] [Full Text] [Related]
56. Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro.
Xia Y; Cheng X; Blossey CK; Wisskirchen K; Esser K; Protzer U
J Immunol Res; 2017; 2017():4828936. PubMed ID: 28367455
[TBL] [Abstract][Full Text] [Related]
57. (4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry.
Chung CY; Liu CH; Wang GH; Jassey A; Li CL; Chen L; Yen MH; Lin CC; Lin LT
Sci Rep; 2016 Jul; 6():29969. PubMed ID: 27426693
[TBL] [Abstract][Full Text] [Related]
58. Aloperine inhibits hepatitis C virus entry into cells by disturbing internalisation from endocytosis to the membrane fusion process.
Lv XQ; Zou LL; Tan JL; Li H; Li JR; Liu NN; Dong B; Song DQ; Peng ZG
Eur J Pharmacol; 2020 Sep; 883():173323. PubMed ID: 32622669
[TBL] [Abstract][Full Text] [Related]
59. New HCV therapies on the horizon.
Vermehren J; Sarrazin C
Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
[TBL] [Abstract][Full Text] [Related]
60. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
